サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) -– By Region (North America, Europe, APAC and RoW), By Country (US, Canada, UK, Germany, France, China, India, Japan)

ヒトパピローマウイルス(HPV)ワクチンの世界市場分析:エンドユーザー別(男性・女性)、年齢層別(未成年・成人)、地域別(北アメリカ・ヨーロッパ・APAC・その他)、国別(アメリカ・カナダ・イギリス・ドイツ・フランス、中国、インド、日本)

レポート概要

本レポートは、広範囲に及ぶ一次調査(業界専門家、企業、利害関係者からのインプット)および二次調査を通じて、エンドユーザー別(男性・女性)、年齢層別(未成年・成人)、地域別(北アメリカ・ヨーロッパ・APAC・その他)、国別(アメリカ・カナダ・イギリス・ドイツ・フランス、中国、インド、日本)に世界のヒトパピローマウイルス(HPV)ワクチン市場を分析します。

世界のヒトパピローマウイルス(HPV)ワクチン市場は、2017~2022年にかけて4.18%のCAGRで成長すると見込まれています。女性のHPVワクチン市場のセグメントは、ここ数年の間、注目すべき割合で成長しており、HPV関連の致命的疾患に関する認識向上、可処分所得の増加に伴う医療支出の上昇に裏付けされて、予測期間に成長すると見込まれています。地域別に見ると、2017年に、北アメリカが、最大シェアを占めました。北アメリカ地域の力強い成長率を推進する主な要因には、低用量の投与スケジュールを持つ第2世代HPVワクチンの出現や青年男性へのHPVワクチン接種の推奨拡大、肛門性器癌および中咽頭癌患者の増加、およびHPV罹患率の増加などが挙げられます。

本レポートは、市場規模、シェア、および成長要因に関する統計および情報を提供し、ヒトパピローマウイルス(HPV)ワクチン市場を分析します。また、最先端の市場情報を提供して、意思決定者が堅実な投資評価をするのに役立ちます。さらに、ヒトパピローマウイルス(HPV)ワクチン市場における主な推進要因、課題、機会、最新動向を分析し、主要企業の市場参入戦略を検証します。

■ 調査範囲

  • HPVワクチンの世界市場(実データ:2012-2016、予測期間:2017-2022)
    ➣ HPVワクチンの世界市場 − 規模および成長
    ➣ エンドユーザー別 − 男性および女性
    ➣ 年齢層別 − 未成年および成人
  • 地域市場 − 北アメリカ・ヨーロッパ・APAC・その他(実データ:2012-2016、予測期間:2017-2022)
    ➣ HPVワクチンの世界市場 − 規模および成長
    ➣ エンドユーザー別 − 男性および女性
    ➣ 年齢層別 − 未成年および成人
  • 国別分析 − アメリカ・カナダ・イギリス・ドイツ・フランス、中国、インド、日本
    ➣ HPVワクチンの世界市場 − 規模および成長
    ➣ エンドユーザー別 − 男性および女性
  • その他
    ➣ 市場力学 − 推進要因および抑制要因
    ➣ 市場動向
    ➣ SWOT分析
    ➣ ポーターのファイブフォース分析
    ➣ 市場勢力図
    ➣ 政策および規制情勢
    ➣ 企業分析
      ◇ Merck and Co,
      ◇ GlaxoSmithKline

本レポートは、クライアントの特定の調査要件に応じてカスタマイズできます。

限られたさらなる追加調査に対する追加費用は必要ありません。

レポート詳細

目次

Table of Content

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. HPV Vaccine Market: Product Outlook

5. Global HPV Vaccine Market: Growth and Forecast
5.1. Global HPV Vaccine Market, By Value (2012-2016)
5.2. Global HPV Vaccine Market, By Value (2017-2022)
5.3. Global HPV Vaccine Market - By End-User, By Value
5.3.1. Global HPV Vaccine Market, By Value, % (2016)
5.3.2. Global HPV Vaccine Market, By Value, % (Forecast 2022F)
5.4. Global HPV Vaccine Market, By End-User, By Value (2012-2022)
5.4.1. Male, By Value (2012-2022)
5.4.2. Female, By Value (2012-2022)
5.5. Global HPV Vaccine Market, By Age-Group, By Value (2012-2022)
5.5.1. Adolescent, By Value (2012-2022)
5.5.2. Adult, By Value (2012-2022)

6. North America HPV Vaccine Market: Growth and Forecast
6.1. North America HPV Vaccine Market, By Value (2012-2016)
6.2. North America HPV Vaccine Market, By Value (2017-2022)
6.3. North America HPV Vaccine Market - By End-User, By Value
6.3.1. North America HPV Vaccine Market, By Value, % (2016)
6.3.2. North America HPV Vaccine Market, By Value, % (Forecast 2022F)
6.4. North America HPV Vaccine Market, By End-User, By Value (2012-2022)
6.4.1. Male, By Value (2012-2022)
6.4.2. Female, By Value (2012-2022)
6.5. North America HPV Vaccine Market, By Age-Group, By Value (2012-2022)
6.5.1. Adolescent, By Value (2012-2022)
6.5.2. Adult, By Value (2012-2022)

6.6. North America HPV Vaccine Market: Country Analysis (U.S., Canada)
6.6.1. North America HPV Vaccine Market, Country Share, 2016 (% of Total)
6.6.2. North America HPV Vaccine Market, Country Share, 2022 (% of Total)
6.7. U.S. HPV Vaccine Market: Growth and Forecast
6.7.1. U.S. HPV Vaccine Market, By Value (2012-2016)
6.7.2. U.S. HPV Vaccine Market, By Value (2017-2022)
6.8. U.S. HPV Vaccine Market - By End-User, By Value
6.8.1. Male, By Value (2012-2022)
6.8.2. Female, By Value (2012-2022)
6.9. Canada HPV Vaccine Market: Growth and Forecast
6.9.1. Canada HPV Vaccine Market, By Value (2012-2016)
6.9.2. Canada HPV Vaccine Market, By Value (2017-2022)
6.10. Canada HPV Vaccine Market - By End-User, By Value
6.10.1. Male, By Value (2012-2022)
6.10.2. Female, By Value (2012-2022)

7. Europe HPV Vaccine Market: Growth and Forecast
7.1. Europe HPV Vaccine Market, By Value (2012-2016)
7.2. Europe HPV Vaccine Market, By Value (2017-2022)
7.3. Europe HPV Vaccine Market - By End-User, By Value
7.3.1. Europe HPV Vaccine Market, By Value, % (2016)
7.3.2. Europe HPV Vaccine Market, By Value, % (Forecast 2022F)
7.4. Europe HPV Vaccine Market, By End-User, By Value (2012-2022)
7.4.1. Male, By Value (2012-2022)
7.4.2. Female, By Value (2012-2022)
7.5. Europe HPV Vaccine Market, By Age-Group, By Value (2012-2022)
7.5.1. Adolescent, By Value (2012-2022)
7.5.2. Adult, By Value (2012-2022)

7.6. Europe HPV Vaccine Market: Country Analysis (U.K., Germany, France & Rest of Europe)
7.6.1. Europe HPV Vaccine Market, Country Share, 2016 (% of Total)
7.6.2. Europe HPV Vaccine Market, Country Share, 2022 (% of Total)
7.7. U.K. HPV Vaccine Market: Growth and Forecast
7.7.1. U.K. HPV Vaccine Market, By Value (2012-2016)
7.7.2. U.K. HPV Vaccine Market, By Value (2017-2022)
7.8. U.K. HPV Vaccine Market - By End-User, By Value
7.8.1. Male, By Value (2012-2022)
7.8.2. Female, By Value (2012-2022)
7.9. Germany HPV Vaccine Market: Growth and Forecast
7.9.1. Germany HPV Vaccine Market, By Value (2012-2016)
7.9.2. Germany HPV Vaccine Market, By Value (2017-2022)
7.10. Germany HPV Vaccine Market - By End-User, By Value
7.10.1. Male, By Value (2012-2022)
7.10.2. Female, By Value (2012-2022)
7.11. France HPV Vaccine Market: Growth and Forecast
7.11.1. France HPV Vaccine Market, By Value (2012-2016)
7.11.2. France HPV Vaccine Market, By Value (2017-2022)
7.12. France HPV Vaccine Market - By End-User, By Value
7.12.1. Male, By Value (2012-2022)
7.12.2. Female, By Value (2012-2022)
7.13. Rest of Europe HPV Vaccine Market: Growth and Forecast
7.13.1. Rest of Europe HPV Vaccine Market, By Value (2012-2016)
7.13.2. Rest of Europe Vaccine Market, By Value (2017-2022)

8. Asia-Pacific HPV Vaccine Market: Growth and Forecast
8.1. Asia-Pacific HPV Vaccine Market, By Value (2012-2016)
8.2. Asia-Pacific HPV Vaccine Market, By Value (2017-2022)
8.3. Asia-Pacific HPV Vaccine Market - By End-User, By Value
8.3.1. Asia-Pacific HPV Vaccine Market, By Value, % (2016)
8.3.2. Asia-Pacific HPV Vaccine Market, By Value, % (Forecast 2022F)
8.4. Asia-Pacific HPV Vaccine Market, By End-User, By Value (2012-2022)
8.4.1. Male, By Value (2012-2022)
8.4.2. Female, By Value (2012-2022)

8.5. Asia-Pacific HPV Vaccine Market, By Age-Group, By Value (2012-2022)
8.5.1. Adolescent, By Value (2012-2022)
8.5.2. Adult, By Value (2012-2022)

8.6. Asia-Pacific HPV Vaccine Market: Country Analysis (Japan, China, India)
8.6.1. Asia-Pacific HPV Vaccine Market, Country Share, 2016 (% of Total)
8.6.2. Asia-Pacific HPV Vaccine Market, Country Share, 2022 (% of Total)
8.7. Japan HPV Vaccine Market: Growth and Forecast
8.7.1. Japan HPV Vaccine Market, By Value (2012-2016)
8.7.2. Japan HPV Vaccine Market, By Value (2017-2022)
8.8. Japan HPV Vaccine Market - By End-User, By Value
8.8.1. Male, By Value (2012-2022)
8.8.2. Female, By Value (2012-2022)
8.9. China HPV Vaccine Market: Growth and Forecast
8.9.1. China HPV Vaccine Market, By Value (2012-2016)
8.9.2. China HPV Vaccine Market, By Value (2017-2022)
8.10. China HPV Vaccine Market - By End-User, By Value
8.10.1. Male, By Value (2012-2022)
8.10.2. Female, By Value (2012-2022)
8.11. India HPV Vaccine Market: Growth and Forecast
8.11.1. India HPV Vaccine Market, By Value (2012-2016)
8.11.2. India HPV Vaccine Market, By Value (2017-2022)
8.12. India HPV Vaccine Market - By End-User, By Value
8.12.1. Male, By Value (2012-2022)
8.12.2. Female, By Value (2012-2022)

9. ROW HPV Vaccine Market: Growth and Forecast
9.1. ROW HPV Vaccine Market, By Value (2012-2016)
9.2. ROW HPV Vaccine Market, By Value (2017-2022)

10. Market Dynamics
10.1. Increasing healthcare awareness about Sexually Transmissible Disease
10.2. Development of Healthcare Infrastructure
10.3. Rising global healthcare expenditure and favorable reimbursed policies

11. Market Restraints

12. Market Trends

13. SWOT Analysis - HPV Vaccine Market

14. Porter’s Five Forces Analysis

15. Policy and Regulatory Landscape

16. Company Profiles
16.1. Merck and Co
16.2. GlaxoSmithKline

17. About Us

List of Figures
Figure 1: Global HPV vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 2: World Male Population Estimates, 2017 (In Millions)
Figure 3: World Female Population Estimates, 2017 (In Millions)
Figure 4: World Female Population, Age 10-14 Years Old (2012-2016)
Figure 5: World Male Population, Age 10-14 Years Old (2012-2016)
Figure 6: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 7: Top 10 Most Frequent Cancer in Females, World, (Age-standardised incidence rate per 100,000 women)
Figure 8: Top 10 Most Frequent Cancer Deaths in Females, World, (Age-standardised incidence rate per 100,000 women)
Figure 9: Age-Standardized Cervical Cancer Incidence Rate (per 100,000 women per year), By Region
Figure 10: HPV Related Cancer Cases in Women/ Year, 530,000
Figure 11: HPV Related Cancer Cases in Men/ Year, 39,000
Figure 12: Global HPV Vaccine Market Size, By Value, 2017-2022 (USD Million)
Figure 13: Global HPV vaccine Market Size, By End-User, 2016 (%)
Figure 14: Global HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 15: Global HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)
Figure 16: Global HPV Vaccine Market - By Age Group, By Value 2012-2022 (USD Million)
Figure 17: North America HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 18: North America GDP, 2012-2015 (USD Trillion)
Figure 19: North America GDP, By Select Country, 2016 (USD Trillion)
Figure 20: North America Healthcare Cost Per Capita, By Select Country, 2016 (USD)
Figure 21: North America Female Population, Age 10-14 Years Old (2012-2016)
Figure 22: North America Male Population, Age 10-14 Years Old (2012-2016)
Figure 23: North America HPV Vaccine Market Size, By Value, 2017-2022(USD Million)
Figure 24: North America HPV vaccine Market Size, By End-User, 2016 (%)
Figure 25: North America HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 26: North America HPV Vaccine Market, End-User, By Value 2012-2022 (USD Million)
Figure 27: North America HPV Vaccine Market, By Age Group, By Value 2012-2022 (USD Million)
Figure 28: North America HPV Vaccine Market, Country Share, 2016 (% of Total)
Figure 29: North America HPV Vaccine Market, Country Share, 2022 (% of Total)
Figure 30: U.S. HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 31: U.S. Female Population, Age 10-14 Years Old (2012-2016)
Figure 32: U.S. Male Population, Age 10-14 Years Old (2012-2016)
Figure 33: U.S. Per Capita Healthcare Expenditure, 2012-2016 (In USD)
Figure 34: U.S. HPV vaccine Market Size, By End-User, 2016 (%)
Figure 35: U.S. HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 36: U.S. HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)
Figure 37: Annual Sales of Cervarix vaccines in U.S., (In Million USD) 2012-2016
Figure 38: Canada HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 39: Canada Female Population, Age 10-14 Years Old (2012-2016)
Figure 40: Canada Male Population, Age 10-14 Years Old (2012-2016)
Figure 41: Normal Cytology
Figure 42: Low-Grade lesions
Figure 43: High-Grade lesions
Figure 44: Cervical Cancer
Figure 45: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 46: Canada HPV vaccine Market Size, By End-User, 2016 (%)
Figure 47: Canada HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 48: Canada HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million)
Figure 49: Europe HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 50: Europe, Female Population aged 15+, By Region, 2017 (In Millions)
Figure 51: European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 52: Europe Female Population, Age 10-14 Years Old (2012-2016)
Figure 53: Europe Male Population, Age 10-14 Years Old (2012-2016)
Figure 54: Europe, GDP, By Select Country, 2016 (USD Billion)
Figure 55: Europe Health Spending Per Capita, By Select Country, 2016 (USD)
Figure 56: Europe HPV Vaccine Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 57: Europe HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 58: Europe HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 59: Europe HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)
Figure 60: Europe HPV Vaccine Market - By Age Group, By Value 2012-2022 (USD Million)
Figure 61: Europe HPV Vaccine Market, Country Share, 2016 (% of Total)
Figure 62: Europe HPV Vaccine Market, Country Share, 2022 (% of Total)
Figure 63: Annual Sales of Cervarix vaccines in Europe, (In Million USD) 2012-2016
Figure 64: U.K. HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 65: U.K. Female Population, Age 10-14 Years Old (2012-2016)
Figure 66: U.K. Male Population, Age 10-14 Years Old (2012-2016)
Figure 67: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 68: U.K., Per Capita Healthcare Expenditure, 2012-2016 (In USD)
Figure 69: U.K. HPV Vaccine Market Size, By End User, 2016 (%)
Figure 70: U.K. HPV Vaccine Market Size, By End User, 2022 (%)
Figure 71: U.K. HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)
Figure 72: Germany HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 73: Germany Female Population, Age 10-14 Years Old (2012-2016)
Figure 74: Germany Male Population, Age 10-14 Years Old (2012-2016)
Figure 75: Germany Per Capita Healthcare Expenditure, 2012 - 2014 (In USD)
Figure 76: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 77: Germany HPV Vaccine Market Size, By End User, 2016 (%)
Figure 78: Germany HPV Vaccine Market Size, By End User, 2022 (%)
Figure 79: Germany HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million)
Figure 80: France HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 81: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 82: France Female Population, Age 10-14 Years Old (2012-2016)
Figure 83: France Male Population, Age 10-14 Years Old (2012-2016)
Figure 84: France Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 85: France HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 86: France HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 87: France HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million)
Figure 88: Rest of Europe HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 89: Asia-Pacific HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 90: Asia Female Population, Age 10-14 Years Old (2012-2016)
Figure 91: Asia Male Population, Age 10-14 Years Old (2012-2016)
Figure 92: APAC, GDP, By Select Country, 2016 (USD Billion)
Figure 93: APAC Health Expenditure Per Capita, Public and Private, By Select Country, 2016 (USD)
Figure 94: Asia-Pacific HPV Vaccine Market Size, By Value, 2017-2022 (USD Million)
Figure 95: Asia-Pacific HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 96: Asia-Pacific HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 97: Asia-pacific HPV Vaccine - End-User, By Value 2012-2022 (USD Million)
Figure 98: Asia-Pacific HPV Vaccine Market - Age Group, By Value 2012-2022 (USD Million)
Figure 99: Asia-Pacific HPV Vaccine Market, Country Share, 2016 (% of Total)
Figure 100: Asia-Pacific HPV Vaccine Market, Country Share, 2022 (% of Total)
Figure 101: Japan HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 102: Japan HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 103: Japan HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 104: Japan HPV Vaccine - End-User, By Value 2012-2022 (USD Million)
Figure 105: China HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 106: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 107: China Female Population, Age 10-14 Years Old (2012-2016)
Figure 108: China Male Population, Age 10-14 Years Old (2012-2016)
Figure 109: China Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 110: China HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 111: China HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 112: China HPV Vaccine - By End-User, By Value 2012-2022 (USD Million)
Figure 113: India HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 114: India Female Population, Age 10-14 Years Old (2012-2016)
Figure 115: India Male Population, Age 10-14 Years Old (2012-2016)
Figure 116: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 117: India HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 118: India HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 119: India HPV Vaccine - By End-User, By Value 2012-2022 (USD Million)
Figure 120: Rest of Asia-Pacific HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 121: ROW HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 122: ROW HPV Vaccine Market Size, By Value, 2017-2022 (USD Million)
Figure 123: Africa Female Population, Age 10-14 Years Old (2012-2016)
Figure 124: Africa Male Population, Age 10-14 Years Old (2012-2016)
Figure 125: Prevalence of Cervical Cancer, among women in Africa (Patients per 100,000 (2012-2016)
Figure 126: Prevalence of Cervical Cancer among female in Brazil (Patients per 100,000 (2012-2016)
Figure 127: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 128: Annual Sales of HPV vaccines, By leading players, (In Million USD) 2012-2016
Figure 129: Market Share of Leading players in HPV vaccine market, 2016
Figure 130: Merck & Co., Net Sales, 2012-2016 (In million USD)
Figure 131: Merck & Co, Net Sales of Gardasil/Gardasil 9, 2012-2016 (In million USD)
Figure 132: Merck & Co., Net Sales, By Geographic Location, % Share 2016
Figure 133: Merck & Co., Net Revenue, By Business Segment, % Share 2016
Figure 134: GlaxoSmithKline Annual Revenue, 2014-2016 (USD Million)
Figure 135: Sales from Hepatitis Vaccination, GlaxoSmithKline, 2015 - 2016 (USD Million)
Figure 136: GlaxoSmithKline Sales, By Region, 2016 (%)
Figure 137: GlaxoSmithKline, Sales, By Segment 2016 (%)

List of Tables
Table A: Globally approved HPV vaccines, 2016
Table B: HPV Vaccine Market Segmentation Flowchart
Table C: Estimated number of HPV Associated cases in 2017
Table D: Estimated new HPV related cancers cases, 2011, 2012 & 2016
Table E: Newly registered diagnosed cases of HPV related cancer in England, 2016
Table F: Estimated and Predicted HPV related cancer among male and female, 2011, 2012 & 2016
Table G: Estimated and Predicted HPV related cancer among female, 2011, 2012 & 2016
Table H: Key Statistics on HPV burden in Asia
Table I: Estimated HPV related New Cancer Cases and Deaths (Thousands), By Sex, 2015

発刊日

2018/03/22

体裁

PDF / 184ページ

販売価格

2,000USD

発行

Azoth Analytics

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

医薬品原料・製剤 / 創薬一般 / 疾病別治療・領域別治療

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE